L. Harnisch
发表
W. Weber,
L. Harnisch,
A. Jessel,
2002,
Clinical pharmacology and therapeutics.
S. Marshall,
J. Lippert,
L. Harnisch,
2016,
CPT: pharmacometrics & systems pharmacology.
L. Harnisch,
R. Bruno,
P. Chanu,
2019,
Journal of Pharmacokinetics and Pharmacodynamics.
M. Rahbar,
M. Wilkins,
L. Harnisch,
2013,
Pulmonary circulation.
L. Harnisch,
I. Bhattacharya,
A. Heatherington,
2016,
Clinical pharmacology and therapeutics.
P. Chan,
L. Harnisch,
I. Bhattacharya,
2018,
Journal of clinical pharmacology.
S. Nayak,
L. Harnisch,
B. Tammara,
2021,
Drugs in R&D.
L. Harnisch,
B. Tammara,
2017,
CPT: pharmacometrics & systems pharmacology.
A. Kirkham,
L. Harnisch,
B. Laurijssens,
2010,
Cephalalgia : an international journal of headache.
M. Boucher,
L. Harnisch,
C. Vong,
2021,
American Journal of Cardiovascular Drugs.
Min Zhang,
Z. Jing,
C. Vizza,
2017,
BMC Pulmonary Medicine.
W. Weber,
L. Harnisch,
H. Roethig,
1996
.
S. Jönsson,
L. Harnisch,
J. Korth-Bradley,
2017,
Clinical pharmacology and therapeutics.
W. Weber,
L. Harnisch,
K. Rost,
2005,
European Journal of Clinical Pharmacology.
P. Chan,
L. Harnisch,
I. Bhattacharya,
2019,
Clinical and translational science.
R. Finkel,
A. Pestronk,
E. Mazzone,
2019,
Journal of Pharmacokinetics and Pharmacodynamics.
Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy
L. Harnisch,
P. Jayachandran,
S. Neelakantan,
2023,
CPT: pharmacometrics & systems pharmacology.
Population PK and PD Analysis of Domagrozumab in Pediatric Patients with Duchenne Muscular Dystrophy
T. Nicholas,
L. Harnisch,
P. Dua,
2022,
Clinical pharmacology and therapeutics.
JJ Wilkins,
PLS Chan,
J Chard,
2017,
CPT: pharmacometrics & systems pharmacology.
J Chard,
R Kaye,
S Moodie,
2015,
CPT: pharmacometrics & systems pharmacology.
R. Abresch,
K. Abrams,
K. Romero,
2019,
Journal of Pharmacokinetics and Pharmacodynamics.
G. Kearns,
T. Darville,
R. Jacobs,
1995
.
T. Nicholas,
L. Harnisch,
Y. Huh,
2021,
British journal of clinical pharmacology.